David Alan Campbell
President, Co-Founder, CEO & DirectorDr. David Campbell, Ph.D serves as President, Chief Executive Officer Co-Founder and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therapeutics in order to improve patient safety and efficacy for this important class of drugs. Prior to founding Janux, Dr. Campbell was an Entrepreneur in Residence at Avalon Ventures from March 2013 to December 2019. He served as the Chief Scientific Officer of Small Molecules, Iron Horse Therapeutics Inc. and COI Pharmaceuticals Inc. Dr. Campbell has industry experience in drug discovery and development focused on oncology and CNS applications of proprietary PAK inhibitors, anti-bacterial drugs, kinase inhibitors, obesity, osteoporosis and diabetes. Dr. Campbell served as the Chief Scientific Officer for Sitari Pharmaceuticals from November 2013 through August 2019 and for Iron Horse Therapeutics from November 2015 to June 2019. Dr. Campbell served as the President and Chief Executive Officer of Enlibirum from November 2015 through December 2017. Dr. Campbell served as the Vice President of Drug Discovery & Preclinical Sciences at Phenomix Corporation since January 2005 and served as its Vice President of Drug Discovery from May 2003 to January 2005. Dr. Campbell also served as the interim Chief Scientific Officer of RQx, another Avalon portfolio company, that developed novel anti-bacterial drugs and was partnered with Genentech. He served as a Member of the Phenomix Corporation executive team since 2003, most recently as an Executive Officer and Senior Vice President of Discovery & Development with responsibility for all drug discovery and development thru early clinical development to proof of concept in humans. Prior to joining Phenomix, Dr. Campbell served as the Senior Vice President of Chemical Sciences of ActivX Biosciences Inc. from 2001 to 2003. He began his career at Affymax Research Institute. Prior to his tenure at ActivX, he served as the Director of Discovery Chemistry at Bayer Corporation and held positions of increasing responsibility at Affymax/Glaxo-Wellcome, culminating in his position as Director of Discovery Chemistry. Dr. Campbell holds three sole-authored and fifteen jointly authored patents and has co-authored 30 original papers. He conducted post-doctoral studies at the University of California, Berkeley after receiving a PhD in organic chemistry and M.S. degree in Chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College.
Positions
- Company NameJanux Therapeutics, Inc.Stock CodeJANXPositionPresident, Co-Founder, CEO & DirectorColleagues
- RWRonald W. BarrettIndependent Chairperson
- TDThomas DiraimondoChief Scientific Officer
- JDJaneen DoyleChief Corporate & Business Development Officer
- MWMatt WhitmireVice President of Finance
- MDMaria DobekVice President of Accounting
- JSJake SimsonIndependent Director
- VLVickie L. CappsIndependent Director
- WKWinston KungIndependent Director
